Hidroferol Semanal (Calcifediol Monohydrate)

Hidroferol Semanal is indicated for the prevention and treatment of vitamin D deficiency and for supporting calcium balance when dietary intake is inadequate.

• Prevention of vitamin D deficiency in adults, adolescents, and elderly individuals.
• Treatment of documented low serum 25‑hydroxyvitamin D concentrations.
• Adjunctive support for bone health in persons with reduced calcium absorption.
• Management of secondary hyperparathyroidism related to vitamin D insufficiency.
• Use in individuals with limited sun exposure or malabsorption conditions.
• Seasonal supplementation during winter months when endogenous synthesis declines.

• Calcifediol monohydrate is the 25‑hydroxy form of vitamin D₃ that circulates in plasma. After oral absorption, it binds to vitamin D‑binding protein and is transported to the liver and kidneys, where it is further hydroxylated to calcitriol, the hormonally active form. Calcitriol interacts with intracellular vitamin D receptors (VDR) to regulate gene transcription, enhancing intestinal absorption of calcium and phosphate and promoting bone mineralization.

Like other vitamin D preparations, Hidroferol Semanal may be associated with a range of adverse reactions, most of which are dose‑related and reversible.

Common

• Mild gastrointestinal discomfort such as nausea or abdominal bloating.
• Transient headache or fatigue.
• Slight increase in serum calcium without symptoms.

Serious

• Hypercalcemia presenting with polyuria, polydipsia, or cardiac arrhythmia.
• Nephrolithiasis (kidney stone formation).
• Hypercalciuria leading to renal impairment.
• Severe allergic reaction (e.g., urticaria, angioedema).

When using Hidroferol Semanal, certain conditions and patient factors require careful consideration to minimize risk.

• Assess baseline serum 25‑hydroxyvitamin D and calcium levels before initiating therapy.
• Use lower weekly doses in patients with renal impairment or a history of hypercalcemia.
• Monitor calcium, phosphate, and renal function periodically during long‑term use.
• Avoid use in individuals with known hypersensitivity to calcifediol or excipients.
• Caution in pregnant or breastfeeding women; consult a healthcare professional.
• Consider dose adjustment in elderly patients with reduced renal clearance.

Hidroferol Semanal can affect the pharmacokinetics or pharmacodynamics of several medicines; awareness of these interactions helps maintain safety.

Avoid

• Concomitant high‑dose vitamin D or calcium supplements that may precipitate hypercalcemia.
• Thiazide diuretics, which reduce urinary calcium excretion and increase hypercalcemia risk.
• Lithium therapy, which can potentiate hyperparathyroidism effects.

Use with caution

• Corticosteroids, which may diminish vitamin D effectiveness and require monitoring.
• Anticonvulsants (e.g., phenytoin, phenobarbital) that increase vitamin D metabolism.
• Bisphosphonates, where combined effects on calcium balance should be observed.
• Loop diuretics, requiring periodic calcium assessment.